Zacks Investment Research upgraded shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a sell rating to a hold rating in a report issued on Wednesday.
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
AGLE has been the subject of several other reports. BMO Capital Markets assumed coverage on Aeglea Bio Therapeutics in a report on Thursday, June 14th. They set an outperform rating and a $21.00 price objective for the company. Wells Fargo & Co lowered Aeglea Bio Therapeutics from an outperform rating to a market perform rating in a report on Tuesday, September 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Aeglea Bio Therapeutics currently has a consensus rating of Buy and an average price target of $22.50.
Shares of AGLE opened at $9.08 on Wednesday. The company has a market cap of $211.32 million, a P/E ratio of -5.03 and a beta of 0.16. Aeglea Bio Therapeutics has a 12 month low of $3.75 and a 12 month high of $12.00.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.10). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 57.15%. The business had revenue of $2.38 million for the quarter. As a group, research analysts anticipate that Aeglea Bio Therapeutics will post -1.8 EPS for the current fiscal year.
In other Aeglea Bio Therapeutics news, insider Aaron Schuchart sold 6,000 shares of the stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $9.50, for a total transaction of $57,000.00. Following the completion of the transaction, the insider now directly owns 8,400 shares of the company’s stock, valued at $79,800. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 18.30% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC bought a new position in Aeglea Bio Therapeutics during the second quarter valued at $131,000. Rhumbline Advisers bought a new position in shares of Aeglea Bio Therapeutics in the second quarter worth $161,000. A.R.T. Advisors LLC bought a new position in shares of Aeglea Bio Therapeutics in the first quarter worth $183,000. UBS Group AG boosted its holdings in shares of Aeglea Bio Therapeutics by 1,752.6% in the first quarter. UBS Group AG now owns 24,565 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 23,239 shares during the period. Finally, Blair William & Co. IL boosted its holdings in shares of Aeglea Bio Therapeutics by 142.8% in the first quarter. Blair William & Co. IL now owns 27,204 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 16,000 shares during the period. 66.50% of the stock is owned by institutional investors and hedge funds.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Featured Article: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.